(Total Views: 227)
Posted On: 10/02/2024 10:16:00 AM
Post# of 107164
$AIMD #Nasdaq - Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA
Next step will be receiving approval from Taiwan Food and Drug Administration (TFDA)
SAN DIEGO, CA / ACCESSWIRE / September 25, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"
, an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT" and low-dose interferon therapeutics, today announced it has received Institutional Review Board (IRB) approval from the National Taiwan University Hospital for its clinical trial focused on treating oral warts in HIV-positive patients. This trial will evaluate VELDONA®, Ainos' low-dose oral interferon formulation, which has received orphan drug designation from the U.S. Food and Drug Administration ("FDA" , as a potential treatment for HIV-related oral warts.
https://finance.yahoo.com/news/ainos-inc-rece...00346.html
Next step will be receiving approval from Taiwan Food and Drug Administration (TFDA)
SAN DIEGO, CA / ACCESSWIRE / September 25, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"
, an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT" and low-dose interferon therapeutics, today announced it has received Institutional Review Board (IRB) approval from the National Taiwan University Hospital for its clinical trial focused on treating oral warts in HIV-positive patients. This trial will evaluate VELDONA®, Ainos' low-dose oral interferon formulation, which has received orphan drug designation from the U.S. Food and Drug Administration ("FDA" , as a potential treatment for HIV-related oral warts. https://finance.yahoo.com/news/ainos-inc-rece...00346.html
(0)
(0)
